Company Analysis - Celestica Inc (NYSE: CLS) received a "Buy" rating in August 2023, which was reaffirmed in November 2023 [1] - The stock has shown a continuous upward trend since the initial coverage [1] Investment Research Service - Beyond the Wall Investing offers access to institutional-grade market analysis and investment ideas [1] - The service provides a free trial and a 10% discount for new subscribers [1] - Daniel Sereda, chief investment analyst at a family office, leads the investment group and specializes in filtering critical data for investment decisions [1] Analyst Position - The analyst holds a beneficial long position in Celestica Inc (NYSE: CLS) through stock ownership, options, or other derivatives [1]

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles. Analyst's Disclosure: I/we have a beneficial long position in the shares of NVDA, AVGO, TSM either through stock ownership, options, or other derivatives. I wrote this ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Celestica (CLS) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Celestica currently has an average broker ...

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today launched its DS4100, a new 1U 800G per port top-of-rack, leaf/spine switch designed to address the high-bandwidth demands of AI/ML data center networking across enterprise, service provider and cloud provider domains. The DS4100 is the latest addition to Celestica's portfolio of storage, compute and ...

Core Insights - Clearside Biomedical announced positive topline data from the ODYSSEY Phase 2b clinical trial of CLS-AX for treating wet AMD, achieving both primary and secondary outcomes [1][2][5] Clinical Trial Overview - The ODYSSEY trial was a randomized, double-masked, parallel-group, active-controlled, multicenter study lasting 36 weeks, involving 60 participants previously treated with standard anti-VEGF therapy [3][4] - Participants were randomized to receive either CLS-AX (1 mg) or aflibercept (2 mg) with a 2:1 ratio [3] Efficacy Results - CLS-AX maintained stable best corrected visual acuity (BCVA) and central subfield retinal thickness (CSRT) throughout the trial [5][6] - 67% of CLS-AX participants did not require additional treatment up to 6 months, with a significant reduction in treatment burden by 84% compared to prior injections [1][6] Safety Profile - CLS-AX demonstrated a positive safety profile with no ocular or treatment-related serious adverse events reported throughout the trial [1][6] - The treatment was well-tolerated, with similar discontinuation rates between CLS-AX and aflibercept groups [6] Future Development - The positive results support advancing CLS-AX into Phase 3 development, with the potential for a flexible maintenance dosing regimen between 3 to 6 months [2][5] - The company aims to provide a new treatment option with meaningful efficacy and safety benefits for patients with wet AMD [2][8] Technology and Delivery Method - CLS-AX utilizes Clearside's proprietary SCS Microinjector for suprachoroidal delivery, allowing targeted treatment to the back of the eye [8][11] - This method may offer advantages over existing therapies by achieving pan-VEGF blockade and potentially longer-lasting effects [8][11] Market Context - Wet AMD is a leading cause of vision loss, affecting approximately 11 million patients in the U.S., with significant economic impacts estimated at $49 billion [9] - Current treatments require frequent injections, leading to a high treatment burden and reduced patient compliance [9]

Stock Performance - Celestica's stock has returned +27.6% over the past month, outperforming the Zacks S&P 500 composite's +5.4% change [2] - The Zacks Electronics - Manufacturing Services industry, which Celestica is part of, has gained 19.3% during the same period [2] Earnings Estimates - Celestica is expected to post earnings of $0.92 per share for the current quarter, representing a year-over-year change of +41.5% [5] - For the current fiscal year, the consensus earnings estimate of $3.65 points to a change of +50.2% from the prior year [5] - For the next fiscal year, the consensus earnings estimate of $3.99 indicates a change of +9.3% from the previous year [6] - The Zacks Consensus Estimate for earnings has remained unchanged over the last 30 days for both the current quarter and fiscal year [5][6] Revenue Growth - The consensus sales estimate for the current quarter is $2.41 billion, representing a year-over-year change of +18% [9] - For the current fiscal year, the sales estimate is $9.47 billion, indicating a change of +18.9% [9] - For the next fiscal year, the sales estimate is $10.28 billion, representing a change of +8.5% [9] - Celestica reported revenues of $2.39 billion in the last reported quarter, a year-over-year change of +23.3% [9] - The company beat consensus revenue estimates by +6.33% in the last quarter [10] Valuation - Celestica is graded A on the Zacks Value Style Score, indicating it is trading at a discount to its peers [14] - The company's valuation metrics suggest it may be undervalued compared to its historical values and industry peers [12][14] Earnings Surprise History - Celestica reported EPS of $0.91 for the last quarter, compared to $0.55 a year ago, representing a +10.98% surprise [9][10] - The company has beaten consensus EPS estimates in each of the trailing four quarters [10] - Celestica has also topped consensus revenue estimates in each of the trailing four quarters [10] Zacks Rank - Celestica has a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][15]

TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Celestica's third quarter financial results conference call and virtual investor meeting will take place on Wednesday, October 23. The conference call start time is 5:00pm ET. Financial results will be released after market close. During the investor meeting, Celestica's management will provide an overview of the business, growth opportunities and its financial outlook. Participants are invited to join the live webcast at the following link. For those unable to par ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

TORONTO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today announced that its Johor, Malaysia operation was honoured with a 2024 Supplier Excellence Award from Lam Research, a global provider of innovative wafer fabrication equipment and services to the semiconductor industry. Recognized from Lam's ecosystem of thousands of suppliers worldwide, Celestica wa ...

Celestica (NYSE: CLS ) has declined by 6.4% since my initial coverage, which was bullish . My updated analysis of CLS suggests that the share price pullback has nothing to do with the company's fundamentals. Celestica's financial As an investor who started my path five years ago with my own capital, I represent a blend of hands on experience and academic background in corporate finance. Due to my relatively young age I thrive on discovering long-duration growth opportunities and actively seek out opportunit ...